CAMBRIDGE, Mass.--(BUSINESS WIRE)--TransMolecular, Inc., a biotechnology company focused on targeted therapies for cancer, today announced the presentation of positive interim Phase 1 data for its intravenous formulation of 131I-TM-601 in recurrent glioma at the American Society for Therapeutic Radiology and Oncology Meeting (ASTRO) in Los Angeles, CA. The Phase 1 study demonstrated that intravenously administered radiolabeled TM-601 is able to cross the blood-brain barrier, bind to tumor tissue in the brain, and produce MR imaging improvement in patients with inoperable malignant glioma. The ASTRO abstract was presented by lead author Dr. John Fiveash, M.D., Radiation Oncology, University of Alabama at Birmingham in a poster session on October 30, 2007.
